gdc
Breast CancerFDA Approvals, News & Updates

Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation

June 2019 Vol 5 No 3

In May 2019, the FDA approved Piqray (alpelisib; from Novartis) tablets, a PIK3CA inhibitor, in combination with Faslodex (fulvestrant; from AstraZeneca), an endocrine therapy, for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer and the genetic alteration, PIK3CA mutation, as detected by an FDA-approved test approved on the same day, the therascreen PIK3CA RGQ PCR Kit.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Piqray was based on a clinical trial with 572 postmenopausal women, and men, with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed during or after an endocrine-based therapy. In patients with a PIK3CA mutation, Piqray plus Faslodex treatment resulted in an average of 11 months without disease progression versus 5.7 months with Faslodex alone.

Some of the side effects associated with Piqray are elevated blood sugar, diarrhea, rash, nausea, fatigue, low red blood cell count, decreased appetite, inflammation in the mouth, vomiting, weight loss, low calcium levels, a rare blood-clotting disorder, and hair loss.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Breast CancerLymphomaSurvivorship
FDA Calls Attention to Risk Associated with Breast Implants: Anaplastic Large-Cell Lymphoma
By Kristen Chanley
In February 2019, the FDA issued a letter to raise awareness of the risk for a rare type of lymphoma, BIA-ALCL, that is linked to all types of breast implants. Although this is an uncommon reaction to implants, all women who have or intend to get an implant after breast cancer should be aware of this risk. Learn more about this risk here.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country